Comparison of treatment plans for patients with high-grade brain tumors using two different treatment planning systems in radiotherapy


Yeşil E., Aktan M., Şahin A., Demir H.

Journal of X-ray science and technology, cilt.34, sa.4, ss.479-488, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 4
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1177/08953996261444398
  • Dergi Adı: Journal of X-ray science and technology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Compendex, EMBASE, INSPEC, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Engineering Source (EBSCO)
  • Sayfa Sayıları: ss.479-488
  • Anahtar Kelimeler: high-grade brain tumor, intensity-modulated radiotherapy, treatment planning system
  • Kütahya Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

OBJECTIVE: To compare treatment plans created using the Eclipse and Prowess treatment planning systems for patients diagnosed with high-grade brain tumors in the left temporal lobe and to evaluate target volume coverage and doses delivered to critical organs using intensity-modulated radiotherapy (IMRT) technique. MATERIALS AND METHODS: This retrospective comparative planning study included 15 patients. Plans were created on CT images using step-and-shoot IMRT with 6 MV photons. Eclipse used the Pencil Beam Convolution (PBC) algorithm, while Prowess used the Collapsed Cone Convolution (CCCS) algorithm. A total dose of 60 Gy in 30 fractions was prescribed. Dosimetric parameters were analyzed statistically. RESULTS: Both TPSs achieved comparable target coverage, with no significant differences in conformity and homogeneity indices (p = 0.075 and p = 0.590, respectively) or dose-volume parameters (D95, D98, D2; p > 0.05). Eclipse provided significantly lower doses to the ipsilateral lens, brainstem, left optic nerve, cochlea, and whole brain V40 (p < 0.05). CONCLUSION: Both TPSs demonstrated adequate target coverage; however, Eclipse achieved statistically significant dose reductions in several critical structures, which may have clinical relevance in reducing toxicity risk.